MONOCYTE/HER2 VACCINE IN BREAST AND OVARIAN CANCER PATIENTS

我们将研究HER2阳性的乳腺癌和卵巢癌患者的细胞和体液免疫反应的要素。患者将接受皮内疫苗接种自体单核细胞，这些单核细胞通过体外培养表达HER2衍生多肽。接种疫苗后，他们将采集外周血、疫苗接种部位、生理盐水对照接种部位和转移肿瘤部位(如果可访问)的样本。从这些部位分离的细胞在体外分析在没有(特异性细胞毒性)或存在(抗体依赖的细胞毒性)体外抗HER2抗体的情况下裂解HER2阳性细胞系的能力时，将研究疫苗诱导的细胞介导性抗肿瘤活性。免疫前后的体液抗肿瘤反应将通过检测血清中循环内源性抗HER2抗体的量来研究。

We will study elements of the cellular and humoral immune responses in HLA-A2+ patients with breast and ovarian cancer whose tumors are HER2 positive. Patients will receive intradermal vaccination with autologous monocytes which have been made to express HER2-derived peptide by in vitro incubation with the peptide. Following vaccination they will have sampling of peripheral blood, vaccination site, saline control vaccination site, and metastatic tumor site (if accessible). Cell-mediated anti-tumor activity induced by vaccination will be studied as cells isolated from these sites are assayed in vitro for ability to lyse HER2 positive cell lines in the absence (specific cytotoxicity) or presence (antibody-dependent cytotoxicity) of in vitro anti-HER2 antibody. Humoral antitumor response before and after vaccination will be studied by assaying serum for the amount of circulating endogenous anti-HER2 antibody.